REFERENCES
- Chen JC, Smith ER, Cahill M, Cohen R, Fishman JB. The opioid receptor binding of dezocine, morphine, fentanyl, butorphanol and nalbuphine. Life Sci. 1993;52:389–396.
- Radbruch L, Sabatowski R, Loick G, Constipation and the use of laxatives: a comparison between transdermal fentanyl and oral morphine. Palliat Med. 2000;14:111–119.
- Schneider E, Brune K. Opioid activity and distribution of fentanyl metabolites. Naunyn Schmiedebergs Arch Pharmacol. 1986;334:267–274.
- King S, Forbes K, Hanks GW, Ferro CJ, Chambers EJ. A systematic review of the use of opioid medication for those with moderate to severe cancer pain and renal impairment: a European Palliative Care Research Collaborative opioid guidelines project. Palliative Med. 2011;25:525–552.
- Kokubun H, Matoba M, Hoka S, Yamada Y, Yago K. Relationship between serum fentanyl concentration and transdermal fentanyl dosage, and intra-individual variability in fentanyl concentration after application of fentanyl patches in patients with cancer pain. Jpn J Pharm Health Care Sci. 2007;33:200–205.
- Levron JC. Pharmacokinetic study of fentanyl administered transdermally (TTS) to patients with liver disorder. Tokyo: Janssen Inc., in house document for NDA 1992.
- Ashburn MA, Ogden LL, Zhang J, Love G, Basta SV. The pharmacokinetics of transdermal fentanyl delivered with and without controlled heat. J Pain. 2003;4:291–297.
- Tempelhoff R, Modica PA, Spitznagel EL Jr. Anticonvulsant therapy increases fentanyl requirements during anaesthesia for craniotomy. Can J Anaesth. 1990;37:327–332.
- Olkkola KT, Palkama VJ, Neuvonen PJ. Ritonavir's role in reducing fentanyl clearance and prolonging its half-life. Anesthesiology. 1999;91:681–685.
- Hallberg P, Marten L, Wadelius M. Possible fluconazole-fentanyl interaction-a case report. Eur J Clin Pharmacol. 2006;62:491–492.
- Kharasch ED, Whittington D, Hoffer C. Influence of hepatic and intestinal cytochrome P4503A activity on the acute disposition and effects of oral transmucosal fentanyl citrate. Anesthesiology. 2004;101:729–737.
- Kokubun H, Matoba M, Okazaki M, Hoka S, Yago K. Evaluation of the 2.5 mg fentanyl patch, applied using the half-side application procedure in patients with cancer pain. Yakugaku Zasshi. 2008;128:447–450.
- Numata C, Teraoka R, Matsuda Y, Investigation of residual amount of fentanyl in used transdermal fentanyl patches: effects of person applying patch and application site. Jpn J Pharm Health Care Sci. 2005;31:599–605.
- Nakayama H, Hasegawa T, Morikawa A, Sugibayashi K. Prediction of serum profile of fentanyl after repeated application of Durotep® patch on skin. Jpn J Ther Drug Monit. 2004;21:248–225.
- Matsuo S, Imai E, Horio M, Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–992.
- McClain DA, Hug CC Jr. Intravenous fentanyl kinetics. Clin Pharmacol Ther. 1980;28:106–114.
- Murphy MR, Hug CC Jr, McClain DA. Dose-independent pharmacokinetics of fentanyl. Anesthesiology. 1983;59:537–540.
- Ariano RE, Duke PC, Sister DS. Population pharmacokinetics of fentanyl in healthy volunteers. J Clin Pharmacol. 2001;41:757–763.
- Feierman DE, Lasker JM. Metabolism of fentanyl, a synthetic opioid analgesic, by human liver microsomes. Role of CYP3A4. Drug Metab Dispos. 1996;24:932–939.
- Tateishi T, Krivoruk Y, Ueng YF, Wood AJJ, Guengerich FP, Wood M. Identification of human liver cytochrome P-450 3A4 as the enzyme responsible for fentanyl and sufentanil N-dealkylation. Anesth Analg. 1996;82:167–172.
- Ohtsuka H, Kobayashi H, Shigeoka T, Torii S, Shimomura H, Nemoto H. Absorption, distribution, metabolism and excretion of 3H-fentanyl after subcutaneous administration in rats. Jpn Pharmacol Ther. 2001;29:865–876.